ClinicalTrials.gg
Active, not recruitingNCT06196827Updated Mar 6, 2026

Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

A Phase 1 interventional study of LX101 in Inherited Retinal Dystrophy Associated With RPE65 Mutations, sponsored by Innostellar Biotherapeutics Co.,Ltd. Active, not recruiting at 2 sites in China. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Innostellar Biotherapeutics Co.,Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jul 2022, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Retinal Dystrophies with a site in China — 6 open to participants now, 9 under way, 1 of them phase 3. Retinal Dystrophies · China.

Started
2022
with 1 other
Phase 1
4 of 10
3 open now
Registered
4th of 10
by date
Lead sponsor
3 of 10
Innostellar Biotherapeutics Co.,Ltd

Among the 10 studies in Retinal Dystrophies with a site in China, this one is one of 2 that started in 2022, is one of 4 in phase 1, and was the 4th registered.

Retinal Dystrophies

60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.

Browse Retinal Dystrophies studies →

Open to participants now

6 of the 10 studies in Retinal Dystrophies with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Retinal Dystrophies with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety, tolerability and efficacy of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dystrophy.

03

Conditions studied

  • Inherited Retinal Dystrophy Associated With RPE65 Mutations

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject and/or their guardian signing a written .

Diagnosed with biallelic RPE65 mutation-associated inherited retinal dystrophy.

Subjects are 6 years of age or older.

Visual acuity of ≤ 20/63 or visual field less than 20 degrees in the eye to be injected.

Exclusion criteria

Exclusion Criteria:

Prior gene therapy for IRD and other hereditary eye diseases.

Pre-existing eye conditions that would interfere with interpretation of study endpoints.

Active intraocular or periocular infections in the study eye.

Lacking of sufficient surviving retinal cells.

Prior ocular surgery within six months.

Complicating systemic diseases or abnormal baseline laboratory values.

Pre-existing systemic diseases that should not discontinue the use of any retinal toxic compounds.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    LX101 Dose 1

    Genetic: LX101

  • Experimental
    LX101 Dose 2

    Genetic: LX101

Interventions

  • GeneticLX101

    Subretinal Administration

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Incidence of ocular and non-ocular AEs and SAEs following LX101 subretinal injection

    Time frame: 12 months

  2. Incidence of dose-limiting toxicity (DLT)

    Incidence of DLT following LX101 subretinal injection at different doses

    Time frame: 1 month

Secondary outcomes

  1. Efficacy of LX101 in study eye

    Changes in BCVA from baseline

    Time frame: 12 months

  2. Efficacy of LX101 in study eye

    Changes in full-field stimulus threshold (FST) from baseline

    Time frame: 12 months

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Dec 2023, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2023
First posted
Jan 9, 2024
StartActual
Jul 2, 2022
Primary completionActual
Dec 6, 2023
CompletionEst.
Dec 2027
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06196827
Lead sponsor
Innostellar Biotherapeutics Co.,Ltd
Responsible party
Sponsor
First posted
Jan 9, 2024
Start date
Jul 2, 2022
Primary completion
Dec 6, 2023
Completion
Dec 2027 (estimated)
Last update
Mar 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion